Aiosyn launched a new website focusing on quantitative AI-based tissue analysis for preclinical studies and AI solutions for clinical laboratories.

Aiosyn is a Dutch healthtech company delivering AI-powered precision pathology solutions to enhance diagnosis and accelerate research in breast cancer and chronic kidney disease. Our algorithms integrate with existing digital pathology software and can be deployed via cloud-based or on-premise installations, ensuring adaptability to diverse laboratory environments. We support digital pathology labs with automated slide quality control (QC) and offer the first IVDR-certified AI solution for mitotic figure counting, improving consistency and efficiency in breast cancer grading. Our NephroPath platform enables quantitative kidney biomarker analysis for CROs and biopharma, helping streamline and scale (pre-)clinical drug development.